Please assess the completion status of the following clinical trial:

Trial Title: ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> or egal18 years with clinical follow-up at the Montreal Heart Institute Adult Congenital Heart Center~* Systemic right ventricle (transposition of great vessels and atrial switch or congenitally corrected transposition of great vessels)~* Moderate to severe systemic right ventricle dysfunction by transthoracic echocardiography (TTE) or right ventricle ejection fraction (RVEF) \<40% by MRI~* NYHA Functional class II-III symptoms or peak exercise capacity \<80% of predicted on a previous standard treadmill exercise stress test (usually done every two years in our congenital clinic).~* Ability to provide informed consent to the study~* Access or own a telephone and/or access to internet connection for teleconference call~* Own a mailing address to receive the medication by post (FedEx or Dicom)~* Able to perform self-measurement of the blood pressure using Upper Arm Digital Blood Pressure Monitor as recommended by Hypertension Canada.~Exclusion Criteria:~* Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days prior enrolment~* Planned cardiac surgery (e.g., severe tricuspid regurgitation with planned tricuspid valve replacement or repair)~* Previous cardiac transplantation, or on heart transplant wait list~* Myocardial infarction, stroke, or open-heart surgery in the previous 4 weeks~* NYHA Functional class I or IV symptoms~* Symptomatic hypotension (fainting, dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache) with a systolic blood pressure \<100 mmHg at screening, or asymptomatic \<90 mmHg at screening~* eGFR \<30 mL/min/1.73 m2~* Reduction in eGFR \>35% from screening to randomization~* Potassium \>5.2 mmol/L at screening or \>5.4 mmol/L at randomization~* Known history of angioedema related to previous ACEI or ARB therapy or patients with a history of hereditary or idiopathic angioedema.~* Patients who require concomitant treatment with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) or a renin inhibitor for other indication than heart failure~* Evidence of hepatic disease as determined by any one of the following: serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) values exceeding 3x upper limit of normal, bilirubin \>1.5 mg/dl at screening.~* Unacceptable side effects with ACE-inhibitors or ARBs~* Patient known with bilateral renal artery stenosis~* Cyanosis; substantial left-to-right shunting (Qp/Qs \>1.5); severe mitral, aortic, or pulmonary regurgitation; systemic or pulmonary inflow obstruction with a peak velocity \>1.5 m/s by transthoracic echocardiography; and severe outflow tract obstruction with a peak systolic gradient \>80 mm Hg.~* Inability to provide informed consent~* Unable to exercice~* Pregnant or planned pregnancy during the study~* Breastfeeding~* Severe pulmonary hypertension defined as pulmonary pressure egal or superior to systemic pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sacubitril/Valsartan (Type: EXPERIMENTAL): Treatment with Sacubitril/Valsartan
- Placebo (Type: PLACEBO_COMPARATOR): Treatment with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).